BRPI0414908A - compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal - Google Patents
compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animalInfo
- Publication number
- BRPI0414908A BRPI0414908A BRPI0414908-4A BRPI0414908A BRPI0414908A BR PI0414908 A BRPI0414908 A BR PI0414908A BR PI0414908 A BRPI0414908 A BR PI0414908A BR PI0414908 A BRPI0414908 A BR PI0414908A
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- animal
- human
- raf kinase
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTO DE BENZAZóIS SUBSTITUìDOS, COMPOSIçõES E MéTODOS DE INIBIçãO DA ATIVIDADE RAF QUINASE EM UM HUMANO OU ANIMAL". Novos compostos de benzazole substituídos de fórmula (I), composições e métodos de inibição da atividade kinase Raf em um humano ou animal são fornecidos. As novas composições e compostos podem ser usados sozinho ou em combinação com pelo menos um agente adicional para o tratamento de uma desordem mediada kinase do Raf, tal como o câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/675,927 US8299108B2 (en) | 2002-03-29 | 2003-09-29 | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
PCT/US2004/032161 WO2005032548A1 (en) | 2003-09-29 | 2004-09-29 | Substituted benzazoles and use thereof as inhibitors of raf kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414908A true BRPI0414908A (pt) | 2006-11-07 |
Family
ID=34422104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414908-4A BRPI0414908A (pt) | 2003-09-29 | 2004-09-29 | compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal |
Country Status (13)
Country | Link |
---|---|
US (2) | US8299108B2 (pt) |
EP (1) | EP1675584A1 (pt) |
JP (1) | JP2007507428A (pt) |
KR (1) | KR20060089232A (pt) |
CN (1) | CN1913884A (pt) |
AU (1) | AU2004277405A1 (pt) |
BR (1) | BRPI0414908A (pt) |
CA (1) | CA2539748A1 (pt) |
EA (1) | EA011890B1 (pt) |
IL (1) | IL174431A0 (pt) |
MX (1) | MXPA06003435A (pt) |
WO (1) | WO2005032548A1 (pt) |
ZA (1) | ZA200603418B (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
IL164302A0 (en) * | 2002-03-29 | 2005-12-18 | Chiron Corp | Substituted benzazoles and use thereof as raf kinase inhibitors |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
JP4939220B2 (ja) | 2003-05-15 | 2012-05-23 | アークル インコーポレイテッド | p38の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体 |
CA2526636C (en) | 2003-05-20 | 2012-10-02 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
AU2004281151A1 (en) * | 2003-10-16 | 2005-04-28 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzazoles and use thereof as inhibitors of Raf kinase |
US7829560B2 (en) * | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
EP2258704A1 (en) * | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
WO2006078907A1 (en) * | 2005-01-20 | 2006-07-27 | Amgen Inc. | 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments |
TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
US7939528B2 (en) * | 2005-10-13 | 2011-05-10 | Glaxosmithkline Llc | Heterocycle compounds |
CA2641744C (en) | 2006-02-10 | 2012-09-25 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
MX2009000770A (es) | 2006-07-21 | 2009-01-28 | Novartis Ag | Formulaciones para eteres de piridilo de bencimidazolilo. |
PE20130814A1 (es) | 2006-08-30 | 2013-08-08 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
KR20090126286A (ko) * | 2007-04-05 | 2009-12-08 | 다이이찌 산쿄 가부시키가이샤 | 축합 2 고리형 헤테로아릴 유도체 |
WO2008150015A1 (en) | 2007-06-05 | 2008-12-11 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
JP5270553B2 (ja) | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP2184285B1 (en) * | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
MX2010002772A (es) | 2007-09-21 | 2010-03-31 | Array Biopharma Inc | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus. |
EP2211862A2 (en) * | 2007-10-18 | 2010-08-04 | Novartis AG | Csf-1r inhibitors for treatment of cancer and bone diseases |
JP5579619B2 (ja) * | 2008-12-01 | 2014-08-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
WO2010065893A1 (en) * | 2008-12-05 | 2010-06-10 | Arqule, Inc. | Raf inhibitors and their uses |
CA2754446A1 (en) | 2009-03-05 | 2010-09-10 | Daiichi Sankyo Company, Limited | Pyridine derivative |
US9386994B2 (en) | 2010-06-11 | 2016-07-12 | Smith & Nephew, Inc. | Patient-matched instruments |
WO2012007836A1 (en) | 2010-07-16 | 2012-01-19 | Purdue Pharma .Lp. | Pyridine compounds as sodium channel blockers |
EP2616441B1 (en) | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
CN102276482A (zh) * | 2011-04-11 | 2011-12-14 | 常州大学 | 2-甲氧基-5-溴苯胺的制备方法 |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
WO2014096941A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
CN103435554A (zh) * | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-苯氨基苯并咪唑类化合物及其用途 |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
EP3233087B1 (en) | 2014-12-16 | 2019-10-02 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
CN105949178B (zh) * | 2015-03-09 | 2020-05-26 | 西格莱(苏州)生物医药有限公司 | 一种苯并咪唑类化合物、其制备方法、中间体及应用 |
US10370370B2 (en) | 2015-06-10 | 2019-08-06 | Axovant Sciences Gmbh | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
KR101770310B1 (ko) | 2015-08-24 | 2017-08-24 | 이화여자대학교 산학협력단 | 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물 |
EP3383852A4 (en) * | 2015-11-30 | 2019-08-28 | Children's Medical Center Corporation | COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES |
MX2019003095A (es) | 2016-09-19 | 2019-07-04 | Novartis Ag | Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk. |
CN106674264A (zh) * | 2016-12-20 | 2017-05-17 | 苏州汉德创宏生化科技有限公司 | (2,2,2‑三氟乙氧基)苯硼酸类化合物的合成方法 |
US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
WO2018168899A1 (ja) | 2017-03-15 | 2018-09-20 | 大日本住友製薬株式会社 | ベンズイミダゾール誘導体の製造方法 |
PT3618875T (pt) | 2017-05-02 | 2023-08-07 | Novartis Ag | Terapia de combinação que compreende um inibidor de raf e trametinib |
WO2019014303A1 (en) * | 2017-07-12 | 2019-01-17 | Bristol-Myers Squibb Company | 5-OR 6,6-CHANNEL BICYCLIC CHAINS AND AMINOHETEROCYCLIC AMINOHETEROCYCLIC INHIBITORS FOR THE TREATMENT OF CARDIAC INSUFFICIENCY |
WO2019081486A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | 4H-PYRROLO [3,2-C] PYRIDIN-4-ONE DERIVATIVES |
WO2019133810A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
WO2019156438A1 (en) * | 2018-02-07 | 2019-08-15 | Korea Research Institute Of Chemical Technology | Hetero ring-fused phenyl compounds for inhibiting tnik and medical uses thereof |
WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
US20240307362A1 (en) | 2019-04-24 | 2024-09-19 | Bayer Aktiengesellschaft | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS |
PE20220254A1 (es) | 2019-04-24 | 2022-02-16 | Bayer Ag | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona |
EP3958865A1 (en) | 2019-04-24 | 2022-03-02 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
WO2021198020A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
EP4146639A1 (en) * | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
JP2023554392A (ja) * | 2020-12-16 | 2023-12-27 | アイエフエム デュー インコーポレイテッド | Sting活性に関連する状態を治療するための化合物および組成物 |
TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
WO2023009708A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors |
WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1014953B1 (en) * | 1997-03-05 | 2012-04-25 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
GB9711650D0 (en) * | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
US6211177B1 (en) * | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
RU2260592C9 (ru) | 1999-04-15 | 2017-04-07 | Бристол-Маерс Сквибб Ко. | Циклические ингибиторы протеинтирозинкиназ |
DE60030741T2 (de) * | 1999-09-23 | 2007-09-06 | Astrazeneca Ab | Chinazoline verbindungen als heilmittel |
DE60103136T2 (de) | 2000-03-06 | 2004-10-28 | Smithkline Beecham Plc, Brentford | Imidazolderivate als Raf-Kinase Inhibitoren |
HUP0400651A2 (hu) | 2000-11-07 | 2004-06-28 | Bristol-Myers Squibb Company | Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények |
WO2002044156A2 (en) | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
WO2002076960A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transition metal mediated process |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
IL164302A0 (en) * | 2002-03-29 | 2005-12-18 | Chiron Corp | Substituted benzazoles and use thereof as raf kinase inhibitors |
US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
CA2520124A1 (en) * | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
-
2003
- 2003-09-29 US US10/675,927 patent/US8299108B2/en not_active Expired - Fee Related
-
2004
- 2004-09-29 MX MXPA06003435A patent/MXPA06003435A/es not_active Application Discontinuation
- 2004-09-29 KR KR1020067006470A patent/KR20060089232A/ko not_active Application Discontinuation
- 2004-09-29 EA EA200600689A patent/EA011890B1/ru not_active IP Right Cessation
- 2004-09-29 EP EP04789345A patent/EP1675584A1/en not_active Withdrawn
- 2004-09-29 CN CNA2004800326778A patent/CN1913884A/zh active Pending
- 2004-09-29 BR BRPI0414908-4A patent/BRPI0414908A/pt not_active IP Right Cessation
- 2004-09-29 JP JP2006528331A patent/JP2007507428A/ja not_active Withdrawn
- 2004-09-29 AU AU2004277405A patent/AU2004277405A1/en not_active Abandoned
- 2004-09-29 WO PCT/US2004/032161 patent/WO2005032548A1/en active Application Filing
- 2004-09-29 CA CA002539748A patent/CA2539748A1/en not_active Abandoned
-
2006
- 2006-03-21 IL IL174431A patent/IL174431A0/en unknown
- 2006-04-28 ZA ZA200603418A patent/ZA200603418B/en unknown
-
2012
- 2012-07-24 US US13/556,907 patent/US20120288501A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA06003435A (es) | 2006-06-20 |
US20120288501A1 (en) | 2012-11-15 |
AU2004277405A1 (en) | 2005-04-14 |
US20040122237A1 (en) | 2004-06-24 |
IL174431A0 (en) | 2006-08-01 |
KR20060089232A (ko) | 2006-08-08 |
ZA200603418B (en) | 2007-07-25 |
CA2539748A1 (en) | 2005-04-14 |
CN1913884A (zh) | 2007-02-14 |
EA011890B1 (ru) | 2009-06-30 |
EP1675584A1 (en) | 2006-07-05 |
JP2007507428A (ja) | 2007-03-29 |
US8299108B2 (en) | 2012-10-30 |
EA200600689A1 (ru) | 2006-08-25 |
WO2005032548A1 (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414908A (pt) | compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal | |
BR0308854A (pt) | Benzazolas substituìdas e seus usos como inibidoras de quinase raf | |
DE602004021838D1 (de) | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer | |
MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
TR200103233T2 (tr) | Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri. | |
TW200714604A (en) | Substituted heterocycles and the uses thereof | |
NI200800060A (es) | Bencimidazoles sustituidos como inhibidores de cinasa. | |
TNSN07076A1 (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders | |
BRPI0407897A (pt) | derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
NO20092639L (no) | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav | |
DK2305255T3 (da) | Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere | |
JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
BRPI0510925A (pt) | métodos e composições para cicatrização de ferida | |
ME00275B (me) | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE | |
DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
NO20065368L (no) | Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin | |
ECSP044935A (es) | Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
BRPI0515483A (pt) | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase | |
MX2009007345A (es) | Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo. | |
MXPA05012894A (es) | Benzofuranos 3-sustituidos como agentes terapeuticos. | |
DE602006003224D1 (de) | Substituierte heterocyclen, ihre verwendung als medikament und pharmazeutische zubereitungen, die sie enthalten | |
ATE554753T1 (de) | 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia | |
ATE447955T1 (de) | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) Free format text: ALTERADO DE: CHIRON CORPORATION |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |